National Pension Service Has $39.65 Million Position in Royalty Pharma PLC $RPRX

National Pension Service lowered its holdings in Royalty Pharma PLC (NASDAQ:RPRX) by 4.7% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 707,178 shares of the biopharmaceutical company’s stock after selling 35,262 shares during the period. National Pension Service’s holdings in Royalty Pharma were worth $39,651,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of RPRX. LM Advisors LLC acquired a new position in Royalty Pharma during the fourth quarter valued at $26,000. Blue Trust Inc. boosted its position in Royalty Pharma by 173.4% during the 1st quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 437 shares during the period. Lloyd Advisory Services LLC. acquired a new stake in Royalty Pharma during the 4th quarter worth about $30,000. CoreCap Advisors LLC grew its stake in Royalty Pharma by 89.2% during the 2nd quarter. CoreCap Advisors LLC now owns 876 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 413 shares in the last quarter. Finally, Bessemer Group Inc. grew its stake in Royalty Pharma by 34.7% during the 1st quarter. Bessemer Group Inc. now owns 1,094 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 282 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Insiders Place Their Bets

In other Royalty Pharma news, EVP Christopher Hite sold 100,000 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $59.97, for a total transaction of $5,997,000.00. Following the transaction, the executive vice president directly owned 370,401 shares of the company’s stock, valued at $22,212,947.97. This represents a 21.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 9,099 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $55.88, for a total value of $508,452.12. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 398,197 shares of company stock valued at $22,513,280 over the last quarter. 18.84% of the stock is currently owned by corporate insiders.

Royalty Pharma Stock Performance

Shares of RPRX stock opened at $58.61 on Friday. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.80 and a quick ratio of 2.80. Royalty Pharma PLC has a fifty-two week low of $34.63 and a fifty-two week high of $64.38. The stock’s 50-day moving average is $59.33 and its two-hundred day moving average is $53.62. The firm has a market cap of $33.70 billion, a P/E ratio of 40.42, a PEG ratio of 1.38 and a beta of 0.44.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.05. The business had revenue of $674.14 million during the quarter, compared to analyst estimates of $758.93 million. Royalty Pharma had a return on equity of 30.01% and a net margin of 32.14%. Analysts predict that Royalty Pharma PLC will post 5.32 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 10th. Investors of record on Friday, August 14th were issued a $0.235 dividend. The ex-dividend date was Friday, August 14th. This represents a $0.94 dividend on an annualized basis and a yield of 1.6%. Royalty Pharma’s dividend payout ratio is currently 64.83%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on RPRX shares. Wall Street Zen raised shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Royalty Pharma in a research report on Wednesday, August 12th. TD Cowen upped their price objective on shares of Royalty Pharma from $65.00 to $68.00 and gave the company a “buy” rating in a research note on Tuesday, September 8th. Morgan Stanley reiterated an “overweight” rating and issued a $65.00 price objective on shares of Royalty Pharma in a research note on Thursday, August 6th. Finally, JPMorgan Chase & Co. increased their target price on shares of Royalty Pharma from $58.00 to $62.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $61.29.

About Royalty Pharma

Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to life sciences companies in exchange for rights to receive future royalty payments from commercialized or late-stage therapies. Rather than developing and marketing medicines itself, the company invests in pharmaceutical and biotechnology innovations and seeks to generate income from the resulting royalty streams.

Its portfolio is linked to a range of therapies across areas including oncology, immunology, neuroscience, rare diseases and other specialty markets.